CA2878401C - Modified adeno-associated virus vector compositions - Google Patents
Modified adeno-associated virus vector compositions Download PDFInfo
- Publication number
- CA2878401C CA2878401C CA2878401A CA2878401A CA2878401C CA 2878401 C CA2878401 C CA 2878401C CA 2878401 A CA2878401 A CA 2878401A CA 2878401 A CA2878401 A CA 2878401A CA 2878401 C CA2878401 C CA 2878401C
- Authority
- CA
- Canada
- Prior art keywords
- aav
- nucleic acid
- vector
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668839P | 2012-07-06 | 2012-07-06 | |
| US61/668,839 | 2012-07-06 | ||
| PCT/US2013/031644 WO2014007858A1 (en) | 2012-07-06 | 2013-03-14 | Modified adeno-associated virus vector compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2878401A1 CA2878401A1 (en) | 2014-01-09 |
| CA2878401C true CA2878401C (en) | 2022-07-19 |
Family
ID=49882407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2878401A Active CA2878401C (en) | 2012-07-06 | 2013-03-14 | Modified adeno-associated virus vector compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9540659B2 (enExample) |
| EP (1) | EP2870237B1 (enExample) |
| JP (1) | JP6366581B2 (enExample) |
| CN (1) | CN104619832B (enExample) |
| AU (1) | AU2013287261B2 (enExample) |
| BR (1) | BR112015000161A2 (enExample) |
| CA (1) | CA2878401C (enExample) |
| ES (1) | ES2703177T3 (enExample) |
| HK (1) | HK1210214A1 (enExample) |
| IN (1) | IN2015KN00074A (enExample) |
| RU (1) | RU2679843C2 (enExample) |
| WO (1) | WO2014007858A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104619832B (zh) * | 2012-07-06 | 2021-03-16 | 衣阿华大学研究基金会 | 经修饰的腺伴随病毒载体组合物 |
| ES2759317T3 (es) * | 2014-05-20 | 2020-05-08 | Univ Iowa Res Found | Compuestos terapéuticos para la enfermedad de Huntington |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| US20190000940A1 (en) * | 2015-07-31 | 2019-01-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of aadc deficiency |
| CA3018076A1 (en) * | 2016-03-18 | 2017-09-21 | The Children's Hospital Of Philadelphia | Therapeutic for treatment of diseases including the central nervous system |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| KR20220108216A (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| CN110650673B (zh) | 2016-08-30 | 2024-04-09 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统 |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| SG11201909870SA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| CA3085338A1 (en) * | 2017-12-11 | 2019-06-20 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| AU2019215152A1 (en) | 2018-02-01 | 2020-08-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof |
| JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
| WO2019195444A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
| WO2019195423A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CA3103963A1 (en) * | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| CN113383010B (zh) | 2018-09-28 | 2025-09-09 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| JP2022531809A (ja) * | 2019-05-14 | 2022-07-11 | デューク ユニバーシティ | ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法 |
| EP3999647A1 (en) * | 2019-07-18 | 2022-05-25 | Lysogene | Compositions and methods for the treatment of sanfilippo disease and other disorders |
| KR20220083708A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | Aav 전달 카세트 |
| AU2020367532A1 (en) | 2019-10-17 | 2022-05-12 | Ginkgo Bioworks, Inc. | Adeno-associated viral vectors for treatment of Niemann-Pick disease type C |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| EP4150102A4 (en) * | 2020-05-11 | 2024-05-29 | Gordian Biotechnology, Inc. | Viral delivery vehicle selection |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| MX2023002016A (es) | 2020-08-19 | 2023-06-26 | Sarepta Therapeutics Inc | Vectores de virus adenoasociados para el tratamiento del sindrome de rett. |
| KR20230142576A (ko) * | 2021-02-05 | 2023-10-11 | 메이즈 테라퓨틱스, 인코퍼레이티드 | 스터퍼 폴리뉴클레오티드 서열을 포함하는 벡터 |
| WO2022235614A2 (en) * | 2021-05-04 | 2022-11-10 | Regenxbio Inc. | Novel aav vectors and methods and uses thereof |
| AU2023322484A1 (en) * | 2022-08-09 | 2025-02-13 | University Of Sheffield | Viral vector |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| JPH1033175A (ja) * | 1996-07-24 | 1998-02-10 | Hisamitsu Pharmaceut Co Inc | 組換えアデノ随伴ウイルスベクターの製造方法 |
| US6171855B1 (en) * | 1998-05-28 | 2001-01-09 | The Regents Of The University Of Michigan | Vectors |
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| AU7953900A (en) * | 1999-10-29 | 2001-05-14 | Takara Shuzo Co., Ltd. | Gene transfer method |
| US7132277B1 (en) * | 2000-01-31 | 2006-11-07 | Merck & Co., Inc. | Helper dependent vector system for gene therapy |
| US7387896B2 (en) * | 2003-03-26 | 2008-06-17 | The Regents Of The University Of Michigan | MicroRNA vectors |
| ES2342397T3 (es) * | 2003-10-20 | 2010-07-06 | Nsgene A/S | Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson. |
| WO2009134681A2 (en) * | 2008-04-30 | 2009-11-05 | The Trustees Of The University Of Pennsylvania | Aav7 viral vectors for targeted delivery of rpe cells |
| CA2833905C (en) * | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
| WO2012109667A1 (en) | 2011-02-12 | 2012-08-16 | University Of Iowa Research Foundation | Therapeutic compounds |
| CN104619832B (zh) * | 2012-07-06 | 2021-03-16 | 衣阿华大学研究基金会 | 经修饰的腺伴随病毒载体组合物 |
-
2013
- 2013-03-14 CN CN201380035802.XA patent/CN104619832B/zh active Active
- 2013-03-14 EP EP13812649.5A patent/EP2870237B1/en active Active
- 2013-03-14 US US14/410,983 patent/US9540659B2/en active Active
- 2013-03-14 AU AU2013287261A patent/AU2013287261B2/en active Active
- 2013-03-14 ES ES13812649T patent/ES2703177T3/es active Active
- 2013-03-14 RU RU2015103901A patent/RU2679843C2/ru active
- 2013-03-14 CA CA2878401A patent/CA2878401C/en active Active
- 2013-03-14 WO PCT/US2013/031644 patent/WO2014007858A1/en not_active Ceased
- 2013-03-14 IN IN74KON2015 patent/IN2015KN00074A/en unknown
- 2013-03-14 BR BR112015000161A patent/BR112015000161A2/pt not_active Application Discontinuation
- 2013-03-14 JP JP2015520166A patent/JP6366581B2/ja active Active
- 2013-03-14 HK HK15110883.2A patent/HK1210214A1/xx unknown
-
2017
- 2017-07-07 US US15/644,491 patent/US20170306355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150184197A1 (en) | 2015-07-02 |
| EP2870237A4 (en) | 2015-12-23 |
| BR112015000161A2 (pt) | 2017-06-27 |
| AU2013287261A1 (en) | 2015-01-22 |
| US20170306355A1 (en) | 2017-10-26 |
| WO2014007858A1 (en) | 2014-01-09 |
| CN104619832B (zh) | 2021-03-16 |
| AU2013287261B2 (en) | 2019-03-07 |
| HK1210214A1 (en) | 2016-04-15 |
| JP6366581B2 (ja) | 2018-08-08 |
| US9540659B2 (en) | 2017-01-10 |
| CA2878401A1 (en) | 2014-01-09 |
| CN104619832A (zh) | 2015-05-13 |
| EP2870237B1 (en) | 2018-09-26 |
| JP2015522280A (ja) | 2015-08-06 |
| EP2870237A1 (en) | 2015-05-13 |
| IN2015KN00074A (enExample) | 2015-07-31 |
| ES2703177T3 (es) | 2019-03-07 |
| RU2015103901A (ru) | 2016-08-27 |
| RU2679843C2 (ru) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013287261B2 (en) | Modified adeno-associated virus vector compositions | |
| Bossis et al. | Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles | |
| KR102725731B1 (ko) | 곤충 세포에서의 개선된 ａａｖ 캡시드 생산 | |
| JP2020532981A5 (enExample) | ||
| CN110770344B (zh) | shRNA表达框、携带其的多核苷酸序列及其应用 | |
| AU2018265541A1 (en) | Viral vector production | |
| CA3222723A1 (en) | Aav manufacturing methods | |
| WO2024121778A1 (en) | Improved rep genes for recombinant aav production | |
| CN111527201A (zh) | 修饰的病毒载体及其制备和使用方法 | |
| CN119894919A (zh) | 包含来自三种不同辅助病毒的辅助元件的嵌合辅助核酸分子 | |
| CN119569834A (zh) | 靶向心肌细胞的aav衣壳蛋白变体及其用途 | |
| EP4667577A1 (en) | Itr-rep gene complex | |
| WO2025171001A1 (en) | Compositions and methods for improved production of aav viral vectors | |
| WO2025205770A1 (ja) | スタッファーｄｎａを含む組換えプラスミド | |
| WO2023198685A1 (en) | Method for determining aav genomes | |
| AU2024311687A1 (en) | Stuffer sequences | |
| IL310949A (en) | A method for preparing an adapted adeno-associated virus envelope | |
| HK40112977A (zh) | 用於确定aav基因组的方法 | |
| HK40015201B (zh) | Shrna表达框、携带其的多核苷酸序列及其应用 | |
| HK40015201A (en) | Shrna expression cassette, polynucleotide sequence carrying same, and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180308 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260504 |